LOBBYIST

Jason Van Pelt

121ACTIVITIES

5ORGS REPRESENTED

19BILLS

Revolving door — covered positions

Federal positions Jason held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.

Legislative Director, Senior Legislative Asst, Legislative Asst, Staff Asst: Rep. Ed Whitfield

Organizations represented

Orgs whose LD-2 filings list Jason as an active lobbyist, sorted by activity volume.

Crossroads Strategies, LLC54 activities Pharmaceutical Research and Manufacturers of America (PhRMA)45 activities Advamed:advanced Medical Technology Association15 activities Coalition for 1099-K Fairness4 activities American Association of Colleges of Osteopathic Medicine3 activities

Bills they file on

S. 89111 mentions

S. 52711 mentions

S. 104011 mentions

S. 104111 mentions

S. 109711 mentions

S. 109511 mentions

S. 109611 mentions

H.R. 149210 mentions

S. 83210 mentions

H.R. 53436 mentions

H.R. 71483 mentions

H.R. 23143 mentions

S. 27153 mentions

H.R. 38853 mentions

S. 39893 mentions

+ 4 more bills referenced in their activities

Topics in Filings

Policy topics Jason files on across all their LD-2 activities.

Drug pricing×22

General education about biomedical research and support for scientific funding×18

FY2027 Departments of Labor×16

Health and Human Services, and Education, and Related Agencies Appropriations×16

Inflation Reduction Act×12

Asia, and Europe×12

Discussions regarding international economic policy×12

Japan, the UK, and the European Union×12

340B drug discount program×11

Importation of biopharmaceuticals×11

International pharmaceutical supply chain×11

PBM reform×11

Show all 53 topics (+41 more) ▾

TRICARE Pharmacy Program×11

Pandemic and All-Hazards Preparedness Act×11

Bipartisan Health Care Act×11

Prescription Pricing for the People Act×11

Drug Competition Enhancement Act×11

Affordable Prescriptions for Patients Act×11

Interagency Patent Coordination and Improvement Act×11

Stop STALLING Act×11

Preserve Access to Affordable Generics and Biosimilars Act×11

General issues×11

Medicare Part B reimbursement×11

Valued-Based Payments×11

Biopharmaceutical innovation and patent policy×11

Bayh-Dole march-in rights policy×11

Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients×10

FY2027 Agriculture×10

Rural Development×10

Food and Drug Administration, and Related Agencies Appropriations×10

CMMI Drug Pricing Demonstration Programs×10

EPIC Act×10

Section 232 tariff investigation on branded pharmaceuticals×10

Reimbursement issues×6

General education to advance policies×6

Legislative issues×4

FY2025 Budget Reconciliation Process×3

Discussions regarding implementation×3

Impacting third party repair of medtech×3

Medicare-funded Graduate Medical Education×3

Osteopathic Funding and Representation×3

FAIR Act×3

Community TEAMS Act×3

FY2027 National Defense Authorization Act×3

One Big Beautiful Bill Act×2

Saving Gig Economy Taxpayers Act×2

SNOOP Act×2

Red Tape Reduction Act×2

Antimicrobial resistance×1

Insulin price cap×1

Full-Year Continuing Appropriations and Extensions Act, 2025×1

FY2025 Budget Resolution×1

All bio-pharmaceutical related provisions×1

Issue mix

LDA general-issue codes weighted by activity count.

Medicare/Medicaid20

Trade (domestic/foreign)20

Health Issues17

Pharmacy12

Budget/Appropriations10

Medical/Disease Research/Clinical Labs6

Science/Technology6

Economics/Economic Development6

Labor Issues/Antitrust/Workplace6